Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis’ Zykadia ASCEND-4 Study Close But No Cigar In NSCLC

Executive Summary

The presentation of the full data from Novartis’ ASCEND-4 study of Zykadia show decent efficacy in first-line NSCLC but are unlikely to be enough to overcome doctors’ caution over its tolerability profile, especially with rival Alecensa snapping at its heels.

Advertisement

Related Content

Brain Benefits Boost Roche's Alecensa In ALK Lung Cancer Race
Keeping Track: A Blizzard Of Submissions And A Small Flurry Of Approvals
Zykadia Challenged As Roche’s Alecensa Gets EU Nod
First-Line Japan Alecensa Trial Stopped Early On Benefits
Pfizer's Xalkori rides on in first-line NSCLC

Topics

Advertisement
UsernamePublicRestriction

Register

SC097824

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel